| European Case Law Identifier: | ECLI:EP:BA:2016:T177712.20160602 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 02 June 2016 | ||||||||
| Case number: | T 1777/12 | ||||||||
| Application number: | 01991093.4 | ||||||||
| IPC class: | A61K 38/22 A61P 3/04 A61P 3/06 A61P 3/12 A61P 9/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Peptide PYY[3-36] for treatment of metabolic disorders | ||||||||
| Applicant name: | Amylin Pharmaceuticals, Inc. | ||||||||
| Opponent name: | Glaxo Group Limited Novo Nordisk A/S (opposition withdrawn) |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Main request - requirements of the EPC met (yes) | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t121777eu1.html
Date retrieved: 17 May 2021